HRT is the most cost-effective option, followed by bisphosphonates, for 50-year-old hypothetical females, but some assumptions and limitations apply (including small sample sizes for the calcitonin and raloxifene groups, and a likely selection bias in that bisphosphonate users are more likely to report longer duration of glucocorticoid therapy). Because few guidelines included cost-effectiveness information, consideration of these results may facilitate better management of glucocorticoidinduced osteoporosis. Patients were assumed to receive weekly pulse MTX alone or weekly pulse MTX plus abatacept administered on days 1, 14, and 29, and every 4 weeks thereafter. Costs with drug acquisition, administration and monitoring were considered. Estimations used data from a Phase III clinical trial of abatacept in patients with inadequate response to MTX (AIM) plus secondary data sources. Cost-effectiveness of abatacept was expressed in terms of the incremental cost (2006 Brazil R$) per qualityadjusted life-year (QALY) gained versus MTX therapy alone; lifetime horizons was employed in the analyses. Costs and health effects were discounted at 3% annually. RESULTS: Over the lifetime, abatacept therapy was estimated to yield an average of 1.61 additional QALYs per patient (vs. MTX alone) at a mean incremental cost of R$146.095/QALY (US$83,483, US$1 = R$1.75). CONCLUSION: Abatacept presented the best costeffectiveness ratio vis-à-vis etanercept, adalimumab, and infliximab, with its incremental costs of R$202.581/QALY, R$189.100/QALY and R$236.479/QALY, respectively vs. Methrotexate alone.
PMS19 COST MINIMIZATION AND BUDGET IMPACT ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT IN RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
Saggia MG, Santos EA, Nasciben V Roche Brazil, Sao Paulo, SP, Brazil OBJECTIVE: Rituximab is a monoclonal antibody with demonstrated efficacy (REFLEX trial) in rheumatoid arthritis patients who responded inadequately to anti-TNF drugs (Cohen et al. 2006) . The study assessed the total cost of rituximab therapy in comparison with infliximab, adalimumab, etanercept and abatacept under a private payer perspective in Brazil. A budget impact analysis was performed. METHODS: This study assumed the same efficacy for all drugs, since there has not been any headto-head trial available until now, although indirect comparisons show higher ACR response rates for rituximab. Direct annual medical costs for biological drugs, IV administration, weekly metotrexate (MTX) and routine exams were taken from a panel of Brazilian rheumatologists. Base case dosages considered were: rituximab (2 g every 8 months), abatacept (750 mg at weeks 0, 2, 4 and then every 4 weeks), infliximab (4 mg/kg at weeks 0, 2, 6 and every 8 weeks), adalimumab (40 mg every other week) and etanercept (50 mg every week). Local administration costs were obtained from Scheinberg et al. 2005 . Costs were reported in 2007 Brazilian Reais and discounted at a 5% rate in the BIA. Therapies were evaluated using a 5-year horizon. In order to assess uncertainty, one and two-way sensitivity analyses were performed. RESULTS: In the base case scenario, rituximab therapy resulted in a total annual cost of R$46,388 per patient. Total annual costs per patient for the comparators were: R$79,394 for infliximab, R$90,831 for adalimumab, R$120,351 for etanercept and R$77,118 for abatacept. In the BIA, rituximab therapy resulted in total savings of R$94,201,413 in 5 years considering the population in the private health care system only. Results were sensitive to dosage schedule (rituximab, infliximab and abatacept) and drug costs. CONCLUSION: Results of this study suggest that therapy with rituximab is a dominant alternative for patients with rheumatoid arthritis in the Brazilian private health care system.
PMS20 THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS: AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Simons WR (QoL) information. These data are novel because they are nationally representative, capture the elderly and their expenditure better than managed care databases, and contain direct and indirect costs and QoL measures in the same population. Multiple linear and semi-log regressions were applied to estimate the total annual health care expenditure and income loss associated with RA. Covariates in expenditure equations included demography, comorbidities and overall health status. Semi-log regression for income rendered the distribution of income symmetric. Covariates in the income equations included demography, comorbidities, education, occupation and health status. RESULTS: A total of 136 patients with RA were identified in the data; 76% were women, and 56% were 41-64 years of age. Total annual incremental expenditure associated with RA was $4422 (P < 0.01) with adjusted R 2 of 0.16 in the linear regression and 0.41 in the semi-log regression. 14% of those expenses were paid by the individual or their family, 28% by Medicare, 39% by private insurance and 14% by Medicaid. As expected, deterioration in overall health status increased health care expenditures monotonically. In the income equation (adjusted R 2 = 0.39), persons with RA earned $3526 less annually (P = 0.03) than the mean income of $26,594 consistent with the US Census Bureau, translating into a 13% decrease. Income increased with education and with improved overall health status. CONCLUSION: Even when controlling for other factors,
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Abstracts the economic impact of rheumatoid arthritis alone is substantial with the indirect productivity or income loss as large as the health care costs.
PMS21 THE RELATIONSHIP BETWEEN COST OF ILLNESS AND DISEASE SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS OF A SYSTEMATIC REVIEW
Richard L, Brown M UCB Celltech, Slough, Berkshire, UK OBJECTIVE: To assess the relationship between economic burden and physical functioning or disease severity in rheumatoid arthritis (RA). METHODS: Medline, Embase, BIOSIS, Derwent Drug File, the Cochrane library and NHS-EED were searched on 12th March 2007 for cost-of-illness (COI) and costeffectiveness studies in RA. RESULTS: A total of 909 unique citations were retrieved. Nine studies presented COI results; with seven studies presenting data on the relationship between direct and indirect costs and physical functioning or disease severity. The Health Assessment Questionnaire (HAQ) was used in three studies to assess functional ability. Higher HAQ scores at baseline were found to be significant predictors of higher future direct costs in two studies. A third study used both HAQ and the Hannover Functional Status Questionnaire (FFbH) to assess functional ability. For patients with an HAQ score <1.2 (or >70% of full FFbH function) the mean annual direct costs were €3225 and indirect costs were €8,811; for patients with an HAQ score between 1.2 and 1.7 (FFbH function of 50 to 70%) mean annual direct costs were €5,661 and indirect costs were €21,580; whilst for patients with an HAQ score higher than 1.7 (FFbH functional status of <50% of normal) mean annual direct costs were €8,403 and indirect costs were €34,915. A further two studies using the FFbH confirmed these findings of increased costs with decreasing functional ability. Finally, in two studies assessing the relationship between disease severity and costs, there was a statistically significant difference (p < 0.001) in both direct and indirect costs for each level increase in disease severity (based on ACR functional classes I, II, III and IV) and increases in costs with increasing disease severity categorised as no disability, mild, moderate and severe. CONCLUSION: The economic burden of RA appears highly dependent on both the level of functional disability and disease severity. The study is an assessment of the economic impact of allopurinol hypersensitivity syndrome (AHS) in a managed care population. METHODS: Due to absence of a specific ICD-9 CM code for AHS, an algorithm was developed using results of a modified Delphi process to identify an AHS episode, and assess its economic impact from claims data. Allopurinol users were identified as those who had a prescription during January 1, 2000 to June 30, 2006. Presence of an AHS episode was assessed during the continuous eligibility period after the first allopurinol prescription. The start date of an AHS episode was termed as the index AHS date, and overall health care costs were computed during a six month period before and after the index AHS date. Statistical differences in costs per patient per six month period pre-and post-AHS were assessed using paired t-tests; differences in proportion with non-zero costs were assessed using McNemar's test. All costs are expressed in 2007 US Dollars.
PMS22 ECONOMIC IMPACT OF ALLOPURINOL HYPERSENSITIVITY SYNDROME
RESULTS: A total of 417 allopurinol users experienced at least one AHS episode during the period following their index allopurinol prescription compared to 124,546 users who did not. The average cost per patient in the six month period following the index AHS date was $8598 higher than the prior 6-month period ($14,338 vs. $5,740, P < 0.001). The cost increase was evident for both medical ($12,032 vs. $4,242, P < 0.001) and pharmacy components ($2,306 vs. $1,498, P < 0.001). The large difference in medical costs was primarily due to large differences in inpatient costs ($7497 vs. $2335, P < 0.001), as a significantly higher proportion had a hospitalization following the AHS episode compared to the pre-index AHS period (40.3% vs. 16.8%, P < 0.001). CONCLUSION: This study found AHS to have a significant economic impact contributing to an almost three fold increase in overall health care costs.
